OBJECTIVES: Biologic treatments for rheumatoid arthritis (RA) vary widely in both the time required to administer treatment and treatment frequency. The primary aim of this study is to quantify the tradeoffs RA patients are willing to make between treatment time and frequency. METHODS: Patients with a self-reported physician diagnosis of moderate-to-severe RA completed a Web-enabled conjointanalysis survey. Severity of self-reported symptoms was determined by the Routine Assessment of Patient Index Data 3 (RAPID3) score. Patients were presented with a series of treatment-choice questions. Each hypothetical treatment included six attributes: response rate, mode of administration, treatment time, treatment frequency, and the risks of immediate, mild and serious treatment reactions. Preference weights were estimated using mixed-logit and were used to calculate the relative importance of treatment attributes and the marginal rate of substitution between treatment time and frequency (MRS). RESULTS: A total of 901 patients completed the survey. The risk of serious treatment reaction was the most important attribute followed by the frequency of treatments and treatment response rate, which were equally important. The risk of a mild treatment reaction was the least important attribute. The MRS implies that if the duration of a 4-hour infusion administered 4 times per year were reduced to 2 hours: 1) the frequency would have to be 10.4 times per year to keep utility constant; 2) the frequency of a 4 hour infusion administered 4 times per year would have to be reduced to 1.6 times per year to generate an equivalent change in utility; and 3) there would be a 50% increase in predicted probability of choosing the treatment if all other attributes of this and other RA treatments were unchanged. CONCLUSIONS: Convenience of RA treatment is important to RA patients. Treatment duration and frequency likely play an important role in patients' choice of RA treatment.
OBJECTIVES:
The availability of biologic therapies has increased the complexity of treatment decisions in juvenile idiopathic arthritis (JIA). There are important differences in the effectiveness, safety, convenience and cost of these treatments compared to other therapeutic agents. High costs and restricted public funding also limit access to biologics in JIA. The objective of this research was to determine parents' willingness-to-pay (WTP) for attributes related to drug treatments in JIA and for profiles reflecting methotrexate (MTX) and etanercept (ETN). METHODS: WTP was determined using parameter estimates from a discrete choice experiment. Marginal WTP was estimated as the ratio of an attribute divided by the negative of the cost attribute. Average WTP for MTX and ETN profiles were estimated using expected compensating variation. Bootstrapping was used to generate 95% confidence intervals for all WTP estimates. RESULTS: Parents had the highest WTP for improved participation in daily activities and pain relief followed by the elimination of treatment side-effects. Parents were willing to pay $2,080 (95% CI $698, $4,065) more for ETN than MTX. When MTX was associated with no side-effects, or was assumed to be equally effective as ETN, parents were willing to pay $985 (95% CI $402, $2,882) more for ETN or no more (95% CI -$596, $488) respectively. CONCLUSIONS: Parents' WTP represents a monetary equivalence of utility for drug treatments in JIA and their desire for treatments that reduced pain, improved daily functioning and eliminate side-effects. These findings align with recent guidelines which recommend more aggressive therapies for children with JIA. Unfortunately, high costs and limited access to biologic drugs in Canada prevents many children from receiving the most effective treatment. Findings from this study will be used to inform policy decisions surrounding the future of prescription drug programs for JIA and other chronic pediatric conditions.
PMS48 INTRAVENOUSLY ADMINISTERED GOLIMUMAB SIGNIFICANTLY IMPROVES HEALTH RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A PHASE III, PLACEBO-CONTROLLED TRIAL
Westhovens R 1 , Weinblatt ME 2 , Han C 3 , Gathany T 3 , Kim L 4 , Mack M 5 , Lu J 4 , Baker D 4 , Mendelsohn A 6 , Bingham C 7 1 UZ Gasthuisberg, Leuven, Belgium, 2 Brigham and Women's Hospital, Boston, MD, USA, 3 Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 4 Janssen Research & Development, LLC, Spring House, PA, USA, 5 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 6 Centocor Research & Development, Inc., Malvern, PA, USA, 7 Johns Hopkins University, Baltimore, MD, USA OBJECTIVES: To evaluate IV golimumab(GLM) on HRQol and work productivity in RA. METHODS: Patients with active RA despite MTX(Ͼ6TJC&SJC,CRPϾ1.0mg/ dL,and RF and/or anti-CCPϩ) were randomized to placeboϩMTX(placebo group) or GLM2mg/kgϩMTX(GLM group) at wk0,2,and q8wk,thereafter.Patients in placebo group withϽ10% improvement in TJC&SJC from baseline at wk16 entered early escape and received IV GLM2mg/kg infusion at wks16 and 20 and q8wks,thereafter.HRQol was assessed using SF-36 and EQ5D(five-item descriptive system of health states and a visual analog scale[EQ VAS,0-100]).Scores for the five health states were converted into a utility score(EQ5D index,0-1,0ϭdead,1ϭfull health)using the US D1 model.Impact of disease on daily work productivity was assessed using VAS 0-10(0ϭno affect,10ϭaffected very much-).Clinically meaningful improvements were defined as change ofՆ5 points in SF-36 PCS and MCS or a change in magnitude of half of standard deviation in EQVAS and EQ5D index.Correlation of remission measured by DAS28(using CRpϽ2.6) with change in PCS and MCS,and productivity scores were analyzed-.Comparisons performed using ANOVA on van der Waerden normal scores for continuous outcomes or Chi-square test for binary outcomes. RESULTS: At baseline,mean(SD)SF-36 PCS(30.8Ϯ6.95)andMCS(37.6Ϯ11.28)were below the US norm(50).Impact of disease on daily work productivity was 6.4(2.32).Compared to placebo,significantly greater changes were observed in the GLM-treatment group inSF-36 PCS(5.92vs3.19),SF-36MCS(4.91vs1.46),EQVAS scores(11.43vs2.53) and EQ5D index(0.13 vs0.09) at wk12,which were sustained through wk16 and 24(p-valuesϽ0.01).Compared to placebo,a greater proportion of patients in the GLM group achieved clinically meaningful improvement in SF-36PCS,SF36MCS,EQVAS and EQ5Dindex.Significantly greater improvements in 8 SF-36 sub-scores for the GLM group vs placebo,were observed(pϽ 0.001).At wk24,mean change(improvement) from baseline in impact of disease on daily work productivity was significantly better in GLM group vs placebo(-2.78vs-1.03,pϽ0.001).Change in SF-36 and work productivity were correlated with change in DAS28,and those who achieved DAS28 remission had greater improvement in SF-36 PCS,MCS and productivity VAS scores than those who didn't achieve remission. CONCLUSIONS: IV GLM significantly improved HRQol and work productivity in RA. 
PMS49 FATIGUE IS AN INDEPENDENT VARIABLE PREDICTING PHYSICAL FUNCTION AND DAS-28 REMISSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH INTRAVENOUSLY ADMINISTERED GOLIMUMAB: RESULTS FROM A PHASE 3, PLACEBO CONTROLLED CLINICAL TRIAL

OBJECTIVES:
To evaluate the association of fatigue with physical function and disease activity in RA patients and the impact of treatment with IVgolimumab-(GLM)on fatigue. METHODS: GO-FURTHER was a PhaseIII,multicenter, randomized, placebo-controlled study. Adult patients with active RA despite MTX were randomized to placeboϩMTX(placebo group) or IV GLM2mg/kgϩMTX (GLM group) at wk0,2, and q8wks thereafter. Patients in placebo group with Ͻ10% improvement in TJC/ SJC from baseline at wk16 entered early escape and received 2mg/kg GLM infusion at wks16 and 20. Impact on physical function was assessed using the disability index of the HAQ. Fatigue was measured using FACIT-F questionnaire, and clinically meaningful improvement in FACIT-Fatigue was defined as Ն4 point increase in scores. Correlation of FACIT-Fatigue with HAQ and disease activity and remission (DAS28 using CRpϽ2.6) were analyzed using Pearson correlation, or multiple linear and logistic regression models to adjust for other confounding variables (age,CRP,TJC, SJC). Comparisons were performed using ANOVA on van der Waerden normal scores for continuous outcomes or Chi-square test for binary outcomes. RESULTS: At baseline,mean(SD) FACIT-Fatigue score was 25.5(10.54), indicating significant fatigue.Significant correlations of FACIT-Fatigue with HAQ(rϭ-0.62,pϽ0.01) and DAS28 score(rϭ-0.42,pϽ0.01) were observed at baseline.In multiple regression models,baseline FACIT-Fatigue score or change in FACIT-Fatigue at wk24 were correlated with change in HAQ and DAS28 score.Patients with higher FACIT-Fatigue scores at baseline were more likely to achieve DAS28 remission at wk24(pϭ0.024).Compared to placebo,GLM-treated patients had significantly greater improvement in FACIT-Fatigue at wk12(5.4Ϯ10.3 vs. 2.1Ϯ9.0),which was sustained through wk16(7.5Ϯ10.5 vs. 2.2Ϯ9.7) and 24(8.0Ϯ10.8 vs. 2.5Ϯ10.2) (all p-valuesϽ0.001). Compared with placebo,a greater proportion of patients in the GLM group achieved clinically meaningful improvement in FACIT-Fatigue score at wk12(57.5% vs. 42.8%) and wk24(65.8% vs.40.3)(p-valuesϽ0.001). CONCLUSIONS: Fatigue was a significant independent predictor of physical function and disease activity in RA patients.IV GLM significantly improved clinical symptoms of fatigue in RA patients with inadequate response to MTX.
PMS50 BENEFITS IN PATIENT REPORTED OUTCOMES SUPPORTING A "TREAT TO TARGET" PARADIGM FOR INFLIXIMAB -TREATED RA PATIENTS PREVIOUSLY INADEQUATELY RESPONSIVE TO PRIOR ANTI-TNF TREATMENT
improvement from baseline to week 26, in 7 of 8 SF-36 domains, versus non-responders, and 2 to 8 times greater improvement in HAQ. Patients attaining low disease activity (Sub-group C) experienced the greatest differences. For Sub-group B, where cohorts had the most comparable baseline scores, results were statistically significant for HAQ (pϭ0.0012) and 6 of 8 SF-36 domains (pϽ0.01 except roleemotional and mental health domains). CONCLUSIONS: Patients able to attain T2T-related response achieved significantly greater absolute improvement in health status versus non-responders, in HAQ and 6 of 8 SF-36 domains. There may be additional value in adding change scores to threshold values in current T2T objectives for severe patients and consideration of patient functionality may be warranted.
PMS51 SHARED DECISION MAKING BETWEEN PATIENTS AND PHYSICIANS IN THE CHOICE TO INITIATE BIOLOGIC THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS
Bolge S 1 , Schenkel B 1 , Ramesh V 2 , Ingham M 1 1 Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2 Kantar Health, New York, NY, USA OBJECTIVES: To describe the shared decision-making process between patients and physicians when initiating biologic therapy for the treatment of rheumatoid arthritis (RA) from the patient perspective. METHODS: Patients self-reporting a diagnosis of RA completed a self-administered, internet-based questionnaire in the Fall of 2011. A subset of patients currently using a biologic therapy to treat their RA provided details about the decision-making process for initiating their current therapy. RESULTS: A total of 2138 respondents (76% female, mean age 56.4) completed the questionnaire. Of these, 20% (nϭ434) were currently being treated with biologic therapy. Discussions about biologic therapy were most often initiated by a rheumatologist (91%); only a small proportion of patients reported that a primary care physician (4%), the patient themselves (3%), or another (2%) initiated the discussion. During the discussions, physicians most often focused on administration (77%), dosing schedule (77%), side effects (71%), safety risks (64%), importance of long-term use (57%), and importance of concomitant methotrexate use (53%). Patients rated the following as very or extremely influential (4 or 5 on a 5-point Likert scale) on the final decision to initiate biologic therapy: advice or recommendation by physician (76%), co-pay assistance to cover out-of-pocket costs (31%), advice or recommendation from other healthcare professional (28%), patient literature materials from physician office (27%), and information from general websites (22%). Most patients (71%) reported making the decision to start biologic therapy at the time of the initial discussion with their physician; mean time for all patients to make a decision to start biologic therapy was 12.2 days from the time of initial discussion. CONCLUSIONS: Rheumatologists are best positioned to ensure that patients have the necessary information to actively engage in the shared decisionmaking process for initiating biologic therapy. Future research should focus on potential outcomes benefits of shared decision-making.
PMS52
VALIDATION OF REMISSION OF RHEUMATOID ARTHRITIS BY TRADITIONAL DISEASE ACTIVITY SCORE AND PROVISIONAL CRITERIA BY AMERICAN COLLEGE OF RHEUMATOLOGY AND EUROPEAN LEAGUE AGAISNT RHEUMATISM: ANALYSIS BASED ON PATIENT REPORTED OUTCOMES FROM 3 PHASE III CLINICAL TRIALS OF GOLIMUMAB
Han C 1 , Keystone E 2 , Fleischmann R 3 , Smolen JS 4 , Emery P 5 , Genovese M 6 , Doyle M 7 , Hsia E 7 1 Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 2 Mount Sinai Hospital, Toronto, ON, Canada, 3 University of Texas, Dallas, TX, USA, 4 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 5 University of Leeds, Leeds, UK, 6 Stanford University, Palo Alto, CA, USA, 7 Janssen Research & Development, LLC, Spring House, PA, USA OBJECTIVES: Remission by Boolean-based definition(all scores on the TJC and SJC-,CRP(mg/dl), and PGAՅ1) and by SDAI(Ͻ3.3) were proposed by ACR/EULAR.Using patient reported outcomes as anchors, this analysis validated these remission criteria against traditional DAS28(using CRpϽ2.6)remission. METHODS: Efficacy of golimumab(GLM) was assessed in MTX-naïve RA patients(GO-BEFORE, Nϭ637), RA patients with inadequate response to MTX (GO-FORWARD,Nϭ444) and RA patients previously treated with biologic anti-TNF␣ agent(s) with baseline MTX use(GO-AFTER,Nϭ305).Pooled data from patients who received placebo (PBO)ϩMTX, or GLM(50or100mg)ϩMTX,q4wks were used for this analysis.Patient reported outcomes were measured using:HAQ, SF-36 PCS and MCS, FACIT-Fatigue, and VAS 0-10 of impact of RA on daily work productivity.Descriptive statistics were provided for patient reported outcomes among patients in remission as defined remission definitions. RESULTS: Greater proportions of patients treated with GLMϩMTX vs patients treated with PBOϩMTX achieved remission by each remission definition.In the pooled analysis,the remission rate at wk24 was the highest(20.2%)by DAS28 vs remission by SDAI(10.6%, pϽ0.001) and remission by Boolean-based definition(8.6%pϽ0.001).Patients with remission by DAS28 achieved normal physical function(HAQՅ0.5),normal SF-36PCS and MCS(Ն50) by 67.8%,38.4%,62.2%,respectively;these parameters were numerically lower vs. patients with remission by SDAI(81.3%,62.8%,72.1%,respectively) or by Boolean-based definition(82.0%,63.5%,74.3%, respectively). Patients in remission by DAS28 had higher HAQ scores(0.43Ϯ0.49)vs patients in remission by SDAI(0.26Ϯ0.41) or Boolean-based criteria(0.28Ϯ0.44).Similar results were observed in measures of FACIT-Fatigue and productivity VAS scores.Among MTX-naive patients in GO-BEFORE who achieved remission by DAS28,71.3% achieved normal physical function vs 86.9% of those in remission by SDAI and 86.5% of patients in remission by Booleanbased definition.Among anti-TNF␣ experienced patients in GO-AFTER,62.1% of those in remission by DAS28 achieved normal physical function vs. 65.0% of those in remission by SDAI, and 66.7% of patients in remission by Boolean-based definition. CONCLUSIONS: While disease remission has been adapted as a target in the management of RA, more stringent remission criteria proposed by ACR/EULAR can provide optimal patient-reported outcomes.
